Outcomes of liver transplantation for paracetamol (acetaminophen)‐induced hepatic failure

Sheldon C. Cooper, Roland C. Aldridge, Tahir Shah, Kerry Webb, Peter Nightingale, Sue Paris, Bridget K. Gunson, David J. Mutimer, James M. Neuberger – 29 September 2009 – Paracetamol (acetaminophen) hepatotoxicity, whether due to intentional overdose or therapeutic misadventure, is an indication for liver transplantation in selected cases. However, there is a concern that long‐term outcomes may be compromised by associated psychopathology that may predispose patients to further episodes of self‐harm or poor treatment adherence.

Donor mannose‐binding lectin gene polymorphisms influence the outcome of liver transplantation

Carlos Cervera, Domingo Balderramo, Belén Suárez, Jhon Prieto, Francisco Fuster, Laura Linares, Josep Fuster, Asunción Moreno, Francisco Lozano, Miquel Navasa – 29 September 2009 – Mannose‐binding lectin (MBL) is a C‐type lectin produced mainly by the liver that binds to a wide range of pathogens. Polymorphisms at the promoter and exon 1 of the MBL2 gene are responsible for low serum levels of MBL and have been associated with an increased risk of infections. We prospectively analyzed 95 liver transplant recipients.

Kinetics of host immune responses and cytomegalovirus resistance in a liver transplant patient

Kirsten Schaffer, Julie Moran, Margaret Duffy, Aiden P. McCormick, William W. Hall, Jaythoon Hassan – 29 September 2009 – Among solid organ transplant (SOT) recipients, donor‐seropositive/recipient‐seronegative (D+/R−) cytomegalovirus (CMV) status is associated with the highest risk of ganciclovir‐resistant CMV disease, which has been reported for patients receiving oral ganciclovir but not valganciclovir prophylaxis. We report a case of CMV breakthrough infection in a D+/R− liver transplant patient while he was receiving oral valganciclovir.

Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus–infected patients shortly after liver transplantation

Elina Teicher, Chadi Abbara, Jean‐Charles Duclos‐Vallée, Teresa Antonini, Laurence Bonhomme‐Faivre, Delphine Desbois, Didier Samuel, Daniel Vittecoq – 29 September 2009 – The aim of this study was to evaluate the impact of an enfuvirtide‐based antiretroviral (ARV) regimen on the management of immunosuppression and follow‐up in hepatitis C virus (HCV)/hepatitis B virus (HBV)/human immunodeficiency virus (HIV)–coinfected liver transplant patients in comparison with a lopinavir/ritonavir‐based ARV regimen.

Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival

Sadahisa Okamoto, Jonas Wixner, Konen Obayashi, Yukio Ando, Bo‐Göran Ericzon, Styrbjörn Friman, Makoto Uchino, Ole B. Suhr – 29 September 2009 – Liver transplantation (LTx) for familial amyloidotic polyneuropathy (FAP) is an accepted treatment for this fatal disease. However, the long‐term outcome with respect to that of nontransplanted patients has not been fully elucidated. The aim of this study was to compare the long‐term survival of Swedish LTx FAP patients with that of historical controls, especially with respect to the age at onset of the disease and gender.

A report of human herpesvirus 6–associated encephalitis in a solid organ transplant recipient and a review of previously published cases

Christopher Vinnard, Todd Barton, Elliot Jerud, Emily Blumberg – 29 September 2009 – Human herpesvirus 6 (HHV‐6) is a common pathogen among children, classically presenting as fever and rash that resolve without specific therapy (exanthem subitum or roseola infantum). Also identified as a pathogen in hematopoietic cell transplant and solid organ transplant (SOT) recipients, it has been recognized as a cause of limbic encephalitis, characterized by confusion and amnesia, with magnetic resonance imaging findings of T2 hyperintensity of the amygdala and hippocampus.

Subscribe to